All In Biotech

Drug Trial Radar · NCT01610284

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

A Phase III Randomized, Double Blind Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative Locally Advanced or Metastatic Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment

Last checked: Nov 19, 2026Latest source record: Aug 25, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,147 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,147

Actual

Start

Aug 7, 2012

Primary completion

Apr 29, 2015

Study completion Apr 19, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 4, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a multi-center, randomized, double-blind, placebo controlled Phase III study to determine the efficacy and safety of treatment with buparlisib plus fulvestrant versus fulvestrant plus placebo in postmenopausal women with hormone Receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative), locally advanced or metastatic breast cancer (MBC) whose disease has progressed on or after aromatase inhibitor (AI) treatment.

Conditions

  • Breast Cancer

Interventions

  • FulvestrantDrug

    Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)

  • BKM120Drug

    BKM120 100 mg once daily

  • BKM120 matching placeboDrug

    BKM120 matching placebo, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) Based on Local Investigator Assessment - Full Analysis Set (FAS) in Full Population, Main Study Cohort and PI3K Unknown CohortTime frame: Date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to approximately 4 years

Locations

268 sites in 29 countries. Site status is shown where the registry gives one.

  • University of South Alabama / Mitchell Cancer Institute Deptof Mitchell Cancer Inst(2)

    Mobile, Alabama

  • Arizona Oncology Associates Dept of Oncology

    Phoenix, Arizona

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Shapiro and Stafford and Yee and Polanski Study Coordinator

    Arcadia, California

  • Cancer Care Associates Dept.ofCancerCareAssoc.

    Fresno, California

  • St. Jude Heritage Medical Group Virginia Crosson Cancer Center

    Fullerton, California

  • University of California San Diego - Moores Cancer Center UCSD 3

    La Jolla, California

  • Los Angeles Hematology/Oncology Medical Group LA Cancer Network

    Los Angeles, California

  • USC Kenneth Norris Comprehensive Cancer Center Dept.ofNorrisCompCancerCtr (3)

    Los Angeles, California

  • University of California at Los Angeles Dept. of UCLA

    Los Angeles, California

  • Ventura County Hematology and Oncology PMK Medical Group

    Oxnard, California

  • Coastal Integrative Cancer Care

    San Luis Obispo, California

  • Santa Barbara Hematolgy Oncology Medical Group

    Santa Barbara, California

  • Central Coast Medical Oncology Corporation

    Santa Maria, California

  • St Joseph Heritage Healthcare Dept. of RRMG (4)

    Santa Rosa, California

  • Granada Hills Cancer Center

    Valencia, California

  • Kaiser Permanente Northwest Kaiser

    Denver, Colorado

  • Rocky Mountain Cancer Centers RMCC

    Greenwood Village, Colorado

  • Memorial Regional Cancer Center MRCC

    Hollywood, Florida

  • Cancer Specialists of North Florida SC - F2302

    Jacksonville, Florida

  • University of Miami Univ Miami 2

    Miami, Florida

  • MD Anderson Cancer Center - Orlando MD Orlando

    Orlando, Florida

  • Georgia Cancer Specialists SC

    Decatur, Georgia

  • North Shore University Health System

    Evanston, Illinois

  • Cadence Health

    Geneva, Illinois

  • Cancer Care and Hematology Specialists of Chicagoland Niles

    Multiple Locations, Illinois

  • Cancer Center of Kansas CCK

    Wichita, Kansas

  • Mercy Medical Center Mercy Medical SC

    Baltimore, Maryland

  • Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Med Sidney/John Hopkins

    Baltimore, Maryland

  • Frederick Memorial Hospital Fred. Mem. Hosp.

    Frederick, Maryland

  • Maryland Oncology Hematology, P.A. SC

    Rockville, Maryland

  • Massachusetts General Hospital SC

    Boston, Massachusetts

  • West Michigan Cancer Center Dept of Oncology

    Kalamazoo, Michigan

  • Hematology and Oncology Association at Bridgepoint Hem Onc Bridgepoint

    Tupelo, Mississippi

  • Washington University School of Medicine Regulatory

    St Louis, Missouri

  • Hackensack Meridian Health

    Brick, New Jersey

  • The Valley Hospital / Luckow Pavillion

    Paramus, New Jersey

  • Clinical Research Alliance SC-2

    Lake Success, New York

  • Memorial Sloan Kettering Dept Onc

    New York, New York

  • University of Rochester Medical Center Univ Rochester

    Rochester, New York

Showing 40 of 268 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.